Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2013

Filed with the SEC on Nov 8, 2013 and accepted by EDGAR at Nov 8, 2013, 09:47 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-07-01 to 2013-09-30$980.0kus-gaap:Revenues
Revenue9 months2013-01-01 to 2013-09-30$3.5mus-gaap:Revenues
Research and development3 months2013-07-01 to 2013-09-30$20.4mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2013-01-01 to 2013-09-30$49.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2013-07-01 to 2013-09-30−$23.3mus-gaap:OperatingIncomeLoss
Operating income9 months2013-01-01 to 2013-09-30−$59.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2013-07-01 to 2013-09-30$13.0kus-gaap:InterestExpense
Interest expense9 months2013-01-01 to 2013-09-30$842.0kus-gaap:InterestExpense
Net income3 months2013-07-01 to 2013-09-30−$23.1mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income9 months2013-01-01 to 2013-09-30−$59.5mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2013-07-01 to 2013-09-30−$0.29us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2013-01-01 to 2013-09-30−$0.76us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2013-01-01 to 2013-09-30−$52.7mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure9 months2013-01-01 to 2013-09-30$1.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2013-09-30$14.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-09-30$139.9mus-gaap:AssetsCurrent
Total assetsAt period end2013-09-30$181.0mus-gaap:Assets
Current liabilitiesAt period end2013-09-30$16.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-09-30$24.2mus-gaap:Liabilities
Shareholders' equityAt period end2013-09-30$156.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-13-082619. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.